Skip to main content
. 2017 Mar 20;38(5):710–718. doi: 10.1038/aps.2016.161

Figure 1.

Figure 1

In vitro activity of JS-001. (A) In vitroFCA experiments demonstrate that JS-001 specifically binds to the PD-1 antigen and (B) efficiently blocks the PD-1/PD-L1 and PD-1/PD-L2 interactions. Apparent affinity was determined using median fluorescence intensity (MFI). (C) The T cell proliferation response was performed using flow cytometry to determine the CFSE intensity. *P<0.05, **P<0.01 vs hIgG4. #P<0.05, ##P<0.01 vs Nivolumab. (D) IFN-γ and (E) TNF-α levels were determined using ELISA. Nivolumab, positive control; hIgG4, negative control. *P<0.05, **P<0.01 vs hIgG4. #P<0.05, ##P<0.01 vs Nivolumab. Data are shown as the mean±SD from 3 independently analyzed experiments.